The 4S Framework of Medical Education: How to Turn Scientific Content into Clinical Decision-Making and Prescribing Behavior

In practice, the challenge in pharmaceutical marketing is not just to build awareness. It is to help physicians move confidently from content exposure to the adoption of new evidence or therapeutic options in clinical practice.

That journey has become more complex. Medical education has never been so abundant — or so competitive. The problem today is no longer a lack of information. It is overload, fragmentation, and increasing competition for qualified attention.

As the volume of information has exploded and channels have multiplied, access to healthcare professionals has become more selective and constrained. In the U.S., access to HCPs dropped from 60% in 2022 to 45% in 2024, and half of accessible professionals now engage with three or fewer companies.¹ At the same time, expectations are rising for interactions that are more relevant, better integrated, and genuinely useful.

In this environment, the 4S framework of digital behavior offers a valuable lens for rethinking omnichannel strategy in Pharma: Streaming, Scrolling, Search, and Shopping.^2,3 In the medical context, however, the last “S” requires a more nuanced interpretation. More than “purchase,” it represents clinical selection and informed adoption — in other words, the moment when knowledge becomes decision.

This framework is especially useful for pharma marketing leaders because it helps answer a critical question:

How do you turn content exposure into scientific trust — and scientific trust into clinical decision-making and prescribing behavior?

1. Streaming: When Science Must Fit into the Physician’s Routine

In the medical world, streaming goes beyond video. It refers to the continuous, flexible, and recurring consumption of scientific content in formats that fit fragmented schedules.

This includes:

• virtual congresses;
• webinars and roundtables;
• medical podcasts;
• video abstracts;
• expert commentary on studies and clinical guidelines;
• on-demand content hosted in educational hubs.

From a pharma marketing standpoint, the value of streaming lies in three key areas:

1. Expanding reach and qualified frequency without relying exclusively on in-person rep visits or large live congresses.
2. Modulating depth, from quick summaries to long-form educational sessions. This makes it possible to offer smaller or longer content modules that can be consumed at the HCP’s convenience.
3. Building brand memory in a way that feels less intrusive and more useful.

This matters because physicians and other HCPs continue to signal preference for hybrid and virtual educational formats — as long as the content is relevant, available on demand, and respectful of their time.⁴

Strategic implication for Big Pharma:

Streaming should not be treated as a webinar archive. It must function as an editorial architecture.  The real question is not, “Do we have content?” but rather, “Do we have a content system that supports the HCP’s clinical journey?”

The differentiator lies in delivering a planned sequence of content that supports different levels of depth, specialties, and points along the physician journey. In other words, the challenge is not simply to provide content. It is to provide high-value content, in a format aligned with the physician’s routine and within an ethical, compliant communications framework.

2. Scrolling: Discovery Happens Before Search

Scrolling is the stage of passive — or semi-passive — discovery. The physician is not necessarily looking for that specific content, but encounters it because it appears in a feed, an app, a physician group, a scientific portal, or a well-planned remote interaction.

This includes:

• posts on professional networks;
• infographics and visual summaries;
• newsletters;
• notifications in medical apps;
• short-form content delivered through approved channels;
• digital communities and closed groups;
• remote calls supported by technical materials designed for fast consumption.

For pharmaceutical marketers, this stage is decisive because it shapes what will be remembered later. In crowded categories, many brands compete for the same mental real estate. The content that wins is not the one that appears most often — it is the one that appears with greater context, clarity, and usefulness.

But there is a critical point here: in Pharma, scrolling without governance is risk. Feed logic must coexist with regulatory logic.

In the U.S., the FDA, through the Office of Prescription Drug Promotion (OPDP), requires promotional communications to be truthful, balanced, and accurately communicated.⁷

Strategic implication for Big Pharma:

Scrolling content must be built with dual capability — creative and medical-regulatory. In other words, it must be engaging without sacrificing accuracy, and concise without trivializing the evidence.

That is highly relevant to this audience. It means that scientific scrolling content can — and should — be planned as a brand asset, as long as there is transparency, appropriate audience segmentation, and a clear distinction between promotional, educational, and scientific content.

3. Search: When Clinical Intent Becomes Explicit

In the search phase, the logic changes. Physicians leave passive mode and enter problem-solving mode.

Now there is a concrete question:

• Which guideline has changed?
• Is this evidence robust?
• For which patient profile is this evidence most relevant?
• How does this product compare with the current standard of care?
• Is there enough evidence for me to trust this recommendation?

At this stage, the physician turns to:

• PubMed, Embase, and Cochrane;
• society guidelines;
• UpToDate, Medscape, and BMJ Best Practice;
• proprietary scientific portals;
• Medical Affairs content;
• quick-reference materials and evidence-based comparisons.

From a pharma marketing perspective, search is a moment of truth. If the brand has performed well in streaming and scrolling, it has earned attention. But search is where it must sustain credibility. Healthcare professionals do not want just an attractive message; they want content that answers their real question with depth, clarity, and scientific grounding.

This is where many strategies fail. Companies invest heavily in awareness, but deliver a poor experience when the HCP decides to go deeper: broken links, poorly curated literature, hard-to-find assets, summaries without context, overly promotional language, or a lack of clinically useful data.

Strategic implication for Big Pharma:

Search requires much tighter integration between marketing, medical, digital, and compliance. The right asset must exist, be approved, be discoverable, and answer the physician’s real question — not simply support the brand’s preferred narrative.

For pharma marketing leaders, the lesson is clear: there is no strong search experience without a strong scientific foundation. And there is no strong scientific foundation without curation, appropriate language, compliance, and robust content architecture.

4. Selection (“Shopping”): In Pharma, the Right Lens Is Selection and Adoption — Ultimately, Prescribing

In traditional marketing, shopping means purchase. In pharmaceutical marketing, that analogy is too limited. What happens here is more sophisticated: the physician evaluates whether new evidence deserves a place in practice.

That is why, in the pharma context, it makes more sense to interpret the fourth “S” as Selection or Clinical Selection.

This moment may involve:

• adoption of a new therapy;
• a change in treatment sequencing;
• incorporation of a new guideline;
• greater confidence in an already known brand;
• faster, safer choices in a real patient case.

The decision rarely comes from a single channel. It is built through the cumulative effect of multiple experiences:

• the feed that reinforced the message through consistent repetition;
• the content that educated;
• the search that clarified;
• the evidence that was fully understood;
• the interaction that consolidated trust.

In other words, there was enough trust to turn information into action.

This reasoning also helps reposition the role of promotion. In pharmaceutical marketing, promotion should not be seen as mere commercial exposure. It remains relevant when it helps build:

• awareness;
• scientific brand memory;
• trust;
• informed clinical action.

That is exactly why connected models integrating sales, marketing, and medical have become so important. Veeva shows that, despite reduced access, companies operating in a more connected way across these functions create more relevant and trusted relationships with HCPs, respond faster to HCP needs, and improve treatment adoption. The report also indicates that pre-launch education led by MSLs in partnership with KOLs can drive a 1.5x increase in adoption during the first six months post-launch.¹

Strategic implication for Big Pharma:

The goal of omnichannel is not to multiply touchpoints. It is to design a coherent progression from exposure to discovery, from discovery to deeper understanding, and from understanding to adoption.

What This Changes in Marketing Planning

Viewing medical education through the lens of the 4Ss helps organize brand planning more intelligently.

1. Every channel needs a clear role

It makes no sense to treat webinars, social media, remote visits, scientific portals, email, and field force interactions as isolated tactics. Each one plays a role at a predominant stage of the physician journey.

2. Content cannot just be accurate; it must be useful

Physicians do not reward precision alone. They reward applied relevance. A scientifically flawless asset that is not actionable will lose to another that better addresses the physician’s day-to-day clinical question.

That is why marketing and medical must work in close alignment. Once search begins, the HCP expects depth, comparability, and clarity. Without real integration between these functions, the journey breaks down.

3. Frequency without relevance loses value

As access becomes more selective, insisting on volume can worsen the customer experience. The market increasingly rewards timing, personalization, and usefulness over repetition.

4. Omnichannel without governance becomes fragmentation

In regulated markets, being present across multiple channels without a strong editorial and regulatory logic increases complexity and risk. Competitive advantage comes from orchestration, not from multiplying formats.

5. Compliance is part of strategy — not just the final review step

The best-performing brands in this environment are precisely those that manage to be creative within regulatory discipline, not in spite of it.

Final Reflections

The medical education journey is not linear. A physician may discover a topic through scrolling, deepen understanding through search, later watch an educational session via streaming, and only then revise clinical practice. Still, thinking about that journey through the 4Ss helps answer a central question for Big Pharma marketing:

How can brands build scientific experiences that are simultaneously relevant and useful to physicians, effective for the brand, and robust from a regulatory standpoint?

In complex markets, with multiple brands, highly competitive categories, and intense regulatory scrutiny, competitive advantage does not come simply from the volume of content produced. It comes from the ability to orchestrate science, context, creativity, and governance.

That is exactly where scientific communication stops being a tactical deliverable and becomes a strategic brand lever.

In the end, the difference between a brand that merely communicates and one that truly influences clinical decision-making does not lie in content volume. It lies in the ability to integrate science, context, creativity, and ethics into one coherent journey.

At KACHI, we turn scientific evidence into content journeys that help pharmaceutical brands build relevance, trust, and clinical adoption with creativity, rigor, and compliance. If your brand needs a smarter strategy to connect science, channels, and medical decision-making, talk to KACHI.

How to cite this article: KACHI Ciência e Comunicação. The 4S Framework of Medical Education: How to Turn Scientific Content into Clinical Decision-Making and Prescribing Behavior. KACHI Comunicação Científica e Marketing Farmacêutico [Internet]. 2026, Mar 17. Available from: https://kachi.com.br/en/article-4s-medical-education-scientific-content-prescribing

References:

1. As Access Declines, Connected Engagement Creates an Edge. Veeva Pulse Field Trends Report [Internet]. Veeva. 2024. [cited 2026 Mar 17]; Available from: https://www.veeva.com/wp-content/uploads/2024/05/Veeva-Pulse-Report-Top-Insights-1Q24.pdf
2. Yu R, Rodenhausen D, Ariav Y, Sponseller T, Remy C. It’s Time for Marketers to Move Beyond the Linear Funnel [Internet]. BCG Global. 2025 [cited 2026 Mar 17]; Available from: https://www.bcg.com/publications/2025/move-beyond-the-linear-funnel
3. The new consumer decision-making process – Think with Google [Internet]. Google Business. 2025 [cited 2026 Mar 17]; Available from: https://business.google.com/us/think/consumer-insights/new-consumer-decision-making-process/
4. Breuer R, Zurkiya DN, Passmore K, Strom M. How medtechs can meet industry demand for omnichannel engagement [Internet]. 2023 [cited 2026 Mar 17];Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/how-medtechs-can-meet-industry-demand-for-omnichannel-engagement
5. Código de Conduta [Internet]. Interfarma | Associação da Indústria Farmacêutica de Pesquisa. [cited 2026 Mar 17];Available from: https://www.interfarma.org.br/condigo-de-conduta/
6. Ministério da Saúde [Internet]. [cited 2026 Mar 17]; Available from: https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2008/rdc0096_17_12_2008.html
7. Center for Drug Evaluation, Research. The Office of Prescription Drug Promotion (OPDP) [Internet]. U.S. Food and Drug Administration. 2025 [cited 2026 Mar 17]; Available from: https://www.fda.gov/about-fda/cder-offices-and-divisions/office-prescription-drug-promotion-opdp
8. Publicidade e propaganda médicas. Resolução CFM n^o 2.336/2023 [Internet]. [cited 2026 Mar 17]; Available from: https://sistemas.cfm.org.br/normas/arquivos/resolucoes/BR/2023/2336_2023.pdf